Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Case report.

The association of Epstein-Barr virus (EBV) with smooth-muscle tumors was recently reported in the setting of acquired immunodeficiency syndrome (AIDS) and post-transplantation. We report a case of an EBV-associated smooth-muscle tumor arising in a post-transplant (PT) patient who previously was treated successfully for two EBV-associated PT large-cell lymphomas. A 4-year-old girl required cardiac transplantation for dilated cardiomyopathy when she was aged 23 months. Her PT regimen included cyclosporine, azothiaprine, and diltiazem. At 16 months PT, she presented with anemia, guaiac-positive stools, and an abdominal mass diagnosed as diffuse large-cell lymphoma of B-cell phenotype. Immunosuppressive therapy was reduced, and interferon and i.v. immunoglobulin were initiated. She rapidly developed signs of rejection, and a cardiac biopsy was performed, revealing grade IIIB rejection. Subsequently, immunosuppressive therapy increased. At 23 months PT, a biopsy was done of a large pelvic mass that was diagnosed as immunoblastic large-cell lymphoma. After treatment with chemotherapy and retinoic acid, the size of the mass markedly decreased. Follow-up computed tomography scan revealed multiple liver nodules. A needle biopsy of the liver showed a smooth-muscle tumor of indeterminate grade. Both the lymphomas and the smooth-muscle tumor contained EBV within > 95% of tumor cells by Epstein-Barr (EBER1) in situ hybridization, were of strain type A by Epstein-Barr nuclear antigen-2 (EBNA-2) polymerase chain reaction (PCR) and contained an identical 30 base-pair deletion (amino acids 346-355) of the latent membrane protein (LMP)-1 oncogene by PCR analysis. Notably, the initial large-cell lymphoma and the subsequent immunoblastic lymphoma each contained a unique p53 mutation, suggesting that they were distinct. These data suggest that the same virus contributed to the pathogenesis of both the malignant lymphomas and the smooth-muscle tumor.

[1]  E. Jaffe,et al.  Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. , 1996, Leukemia.

[2]  I. Orengo,et al.  Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients , 1995, The Lancet.

[3]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[4]  Yi Fang Liu,et al.  Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. , 1995, Blood.

[5]  R. Parmley,et al.  Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. , 1995, The New England journal of medicine.

[6]  J. Locker,et al.  The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. , 1995, The New England journal of medicine.

[7]  E. Cesarman,et al.  Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. , 1995, Blood.

[8]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[9]  B. Andresen,et al.  Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. , 1994, Blood.

[10]  R. Braylan,et al.  Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type. , 1994, Human pathology.

[11]  N. Raab-Traub,et al.  Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas , 1994, Journal of virology.

[12]  R. Mertelsmann,et al.  BCL-2 induction is part of the strategy of Epstein-Barr virus. , 1994, Leukemia & lymphoma.

[13]  E. Jaffe,et al.  Epstein‐Barr Virus Is Infrequently Identified in Non‐Hodgkin's Lymphomas Associated with Hodgkin's Disease , 1994, The American journal of surgical pathology.

[14]  S. Hamilton-Dutoit,et al.  Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas , 1994 .

[15]  P. Brousset,et al.  Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. , 1993, Blood.

[16]  E. Jaffe,et al.  Epstein-Barr virus-associated T-cell lymphoma in a renal transplant patient. , 1993, The American journal of surgical pathology.

[17]  W. Chan,et al.  Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A virus associated with Hodgkin's disease [published erratum appears in Blood 1993 Oct 1;82(7):2268] , 1993 .

[18]  G. Winberg,et al.  Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. , 1993, Oncogene.

[19]  D. Thorley-Lawson,et al.  All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts , 1993, Journal of virology.

[20]  D. Shibata,et al.  Epstein-Barr virus genotypes in AIDS-associated lymphomas are similar to those in endemic Burkitt's lymphomas. , 1992, Leukemia.

[21]  L. Young,et al.  Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. , 1992, Virology.

[22]  R. Shapiro,et al.  B‐cell lymphoproliferative disorders after bone marrow transplant. An analysis of ten cases with emphasis on epstein–barr virus detection by in situ hybridization , 1991, Cancer.

[23]  E. Jaffe,et al.  Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. , 1991, American journal of clinical pathology.

[24]  E. Kieff,et al.  Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.

[25]  W. Hammerschmidt,et al.  The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels , 1989, Journal of virology.

[26]  Sullivan Jl Epstein-Barr virus and lymphoproliferative disorders. , 1988 .

[27]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[28]  B. Barrell,et al.  Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8 , 1985, Journal of virology.

[29]  J. Sklar,et al.  LYMPHOPROLIFERATIVE DISORDERS IN CARDIAC TRANSPLANT RECIPIENTS ARE MULTICLONAL LYMPHOMAS , 1984, The Lancet.